301
|
Shah RS, Toddywalla V, Maskati BT, Desai AD, Karnik PP, David GF, Anand Kumar TC. Reproductive endocrine effects of intranasal administration of norethisterone (NET) to women. Contraception 1985; 32:135-47. [PMID: 3935371 DOI: 10.1016/0010-7824(85)90102-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Four consecutive menstrual cycles were studied in six healthy parous women. A solvent mixture comprising propylene glycol:ethanol:water (3:3:4) was sprayed intranasally daily using a glass atomizer between days 5 and 24 of the first (control) menstrual cycle. NET was dissolved in the solvent and similarly administered at a daily dose of 100 mcg during the second and third menstrual cycles. Nasal sprays were not administered during the fourth post-treatment cycle. Blood samples were taken during four consecutive cycles between days 8 and 15 and again between days 20 and 24 of the cycle to estimate levels of estradiol (E2), FSH, LH and progesterone (P). These studies revealed that nasal sprays of NET were well accepted and that no adverse clinical effects or menstrual disturbances occurred. NET inhibited ovulation in one cycle. The E2-induced mid-cycle rise in FSH and LH was either suppressed or inhibited in nine out of the 12 treated cycles. P levels in three treated cycles were indicative of luteal inadequacy. These endocrine effects of NET persisted into the post-treatment cycle in two cases.
Collapse
|
302
|
Souka AR, Kamel M, Einen MA, Saleh F, Sallam H. Vaginal administration of a combined oral contraceptive containing norethisterone acetate. Contraception 1985; 31:571-81. [PMID: 3899504 DOI: 10.1016/0010-7824(85)90057-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The effects of vaginal administration of an oral contraceptive pill containing 1 mg of norethisterone acetate and 0.05 mg of ethinyl oestradiol were studied in 20 subjects for a total of 57 cycles. The results show effective ovulation suppression in the two dose regimens used. The lower dose regimen was associated with fewer side effects and no breakthrough bleeding. No significant change was observed in the serum concentration of glucose, total proteins, albumin, cholesterol and HDL after several cycles of treatment in both dose regimens used. It is concluded that vaginal administration of this preparation of oral contraceptives is an effective alternative method of hormonal contraception.
Collapse
|
303
|
Abstract
A crossover study from a standard-dose to a low-dose oral contraceptive was conducted in the Sudan. Reported side effects were very few, with a headache the most frequently reported. Switching to the other pill did not affect the rate of any side effects.
Collapse
MESH Headings
- Adolescent
- Adult
- Clinical Trials as Topic
- Contraceptives, Oral, Combined/administration & dosage
- Contraceptives, Oral, Combined/adverse effects
- Contraceptives, Oral, Hormonal/administration & dosage
- Contraceptives, Oral, Hormonal/adverse effects
- Contraceptives, Oral, Synthetic/administration & dosage
- Contraceptives, Oral, Synthetic/adverse effects
- Drug Combinations
- Ethinyl Estradiol/administration & dosage
- Ethinyl Estradiol/adverse effects
- Ethinyl Estradiol-Norgestrel Combination
- Female
- Humans
- Infant, Newborn
- Mestranol/administration & dosage
- Mestranol/adverse effects
- Norethindrone/administration & dosage
- Norethindrone/adverse effects
- Norgestrel/administration & dosage
- Norgestrel/adverse effects
- Pregnancy
- Random Allocation
- Sudan
Collapse
|
304
|
Abstract
A case is presented of a decidual cast following progesterone therapy, an extraordinarily rare event.
Collapse
|
305
|
Resseguie LJ, Hick JF, Bruen JA, Noller KL, O'Fallon WM, Kurland LT. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974. Fertil Steril 1985; 43:514-9. [PMID: 3987922 DOI: 10.1016/s0015-0282(16)48490-6] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Comparison of a cohort of 988 offspring exposed in utero to exogenous progestins with a matched cohort of unexposed offspring did not result in detection of an association of congenital anomalies with exposure. The conclusions are based primarily on outcomes of pregnancy with exposure to progesterone and 17 alpha-hydroxyprogesterone caproate, and may not apply to androgenic progestins. Offspring exposed to combinations of progestins and estrogens were excluded from this study and may have a different distribution of anomalies.
Collapse
|
306
|
Garza-Flores J, Cardenas S, Rodríguez V, Cravioto MC, Diaz-Sanchez V, Perez-Palacios G. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study. Contraception 1985; 31:361-6. [PMID: 3159544 DOI: 10.1016/0010-7824(85)90004-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A comparative study was undertaken in twenty-four Mexican women who discontinued the use of depo-medroxyprogesterone acetate (DMPA) or norethisterone enanthate (NET-EN) to assess the time required for the return to menses and ovulation. All subjects were exposed to long-acting injectable contraceptives for at least one year, and were followed prospectively. Serum progesterone levels were determined weekly in all subjects beginning 3 months after the last progestogen injection. Mean time to return to ovulation occurred significantly earlier (p less than 0.001) after NET-EN (2.6 months) as compared with DMPA (5.5 months). No correlation between the return to ovarian function and the duration of steroid exposure was found. The overall data was interpreted as demonstrating a clear-cut difference between the two long-acting progestogens in terms of ovulation suppression.
Collapse
|
307
|
Staland B. Continuous treatment with a combination of estrogen and gestagen--a way of avoiding endometrial stimulation. Clinical experiences with Kliogest. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. SUPPLEMENT 1985; 130:29-35. [PMID: 3859973 DOI: 10.3109/00016348509157144] [Citation(s) in RCA: 32] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Nearly 5 years' experience of continuous treatment with a preparation consisting of natural estrogens combined with norethisterone acetate is presented. The effect on both climacteric symptoms and hormonal parameters was good, even though the endometrium remained atrophic or became so. This was the case even when the endometrium was hyperplastic and/or atypical prior to treatment. This treatment appears to be better than those in common use--at least in selected cases.
Collapse
|
308
|
Mattsson LA, Samsioe G. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. SUPPLEMENT 1985; 130:53-8. [PMID: 3859976 DOI: 10.3109/00016348509157148] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Twenty-six peri- and postmenopausal women were treated with daily dose of 2 mg 17-beta-estradiol, 1 mg estriol and 1 mg norethisterone-acetate in a continuous regimen for 12 months. Clinical parameters such as vasomotor symptoms, bleeding patterns and histopathology were recorded. Blood samples were collected before, after 3 months and after 12 months of treatment and were analysed for estradiol-17-beta, estrone, androstenedione in serum and lipoprotein lipids. A marked reduction of hot flushes and sweatings was noted and the number of days with bleeding gradually decreased during treatment, especially in the postmenopausal group of women. No signs of hyperplasia of the endometrium were recorded. A decrease in the serum concentration of testosterone and androstenedione was found during treatment. The reduction in triglycerides in very low density lipoproteins after 3 months, concomitant with a decrease in the cholesterol content of high density lipoproteins, was interpreted as an effect mainly of the progestogen component in the preparation. The present formulation of estrogen-progestogen, continuously administered, may be an appropriate alternative treatment regimen for many women. One proposition of how to treat women with climacteric complaints around the menopause is presented.
Collapse
|
309
|
el-Boulaqi HA, el-Refaie SA, Bassiouny GA, Amin FM. The relation between Trichomonas vaginalis and contraceptive measures. JOURNAL OF THE EGYPTIAN SOCIETY OF PARASITOLOGY 1984; 14:495-9. [PMID: 6512296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
310
|
Banerjee SK, Baweja R, Bhatt RV, Chatterjee A, Choudhury SD, Coyaji B, Engineer AD, Gogoi MP, Hingorani V. Comparative evaluation of contraceptive efficacy of norethisterone oenanthate (200 mg) injectable contraceptive given every two or three monthly. Indian Council of Medical Research Task Force on Hormonal Contraception. Contraception 1984; 30:561-74. [PMID: 6397328 DOI: 10.1016/0010-7824(84)90006-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
A total of 2388 subjects, 1181 for 60 +/- 5-day and 1207 for 90 +/- 5-day treatment regimen with norethisterone oenanthate (NET OEN) 200 mg injection, were observed for 24 months, constituting 28,513 woman-months. This clinical trial represents the largest clinical trial undertaken on NET OEN. The observations indicated that NET OEN given at 60 +/- 5-day intervals provides adequate contraceptive protection. However, as compared to the published studies elsewhere, higher method failures were seen during the first six months of NET OEN usage, when all women were receiving the drug at 60 +/- 5-day intervals. The reasons for this discrepant observation in the present study cannot be explained. The higher method failures reported with 90 +/- 5-day regimen were mainly during the third month following the injection, suggesting reduced contraceptive efficacy of the drug during this period. Thin build women (body weight less than or equal to 40 kg) were at higher risk of involuntary pregnancy. Disrupted menstrual pattern was the major reason for discontinuation ranging between 42-43 per 100 users at the end of 24 months. Amongst these, amenorrhoea was the commonest reason for discontinuation. No change in blood pressure was observed during contraceptive usage. The majority of NET OEN users did not show any change in body weight. The overall continuation rates with NET OEN were lower than those observed in similar conditions with Cu-T 200 mm2 IUCD.
Collapse
|
311
|
Elder MG. Injectable contraception. CLINICS IN OBSTETRICS AND GYNAECOLOGY 1984; 11:723-41. [PMID: 6239732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
312
|
Shaaban MM, Elwan SI, el-Kabsh MY, Farghaly SA, Thabet N. Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation. Contraception 1984; 30:421-30. [PMID: 6440738 DOI: 10.1016/0010-7824(84)90034-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
A longitudinal study of coagulation parameters was carried out on 47 women using the levonorgestrel subdermal implants, NORPLANT. The study comprised measurement of platelet count, prothrombin time, thrombin time, partial thromboplastin time with kaolin, clotting factors I, II, V and VI through XIII, plasminogen, antithrombin III (AT III), alpha 1 antitrypsin, alpha 2 macroglobulin and fibrinogen degradation products. The tests were done at admission and after one, three and six months of NORPLANT use. Parallel and similar studies were done on two groups of oral contraceptive users; the first group used a pill containing 1 mg norethisterone and 50 micrograms mestranol, and the second a pill consisting of 150 micrograms levonorgestrel and 30 micrograms ethinylestradiol. Results from this ongoing study have indicated that women using NORPLANT implants evidenced lack of effects on most of the parameters tested except for factor VII activity which was increased and AT III concentration which was decreased after six months of use. The combined pill users evidenced marked changes in the platelet count, the screening tests and in most of the coagulation-promoting factors; the changes were apparent after three months of use and became more pronounced after six months. The results demonstrate, with marked contrast, that the implants had less pronounced effects on the blood coagulation system than did the combined pills used in this study.
Collapse
|
313
|
Basnayake S, Higgins JE, Miller PC, Rogers SM, Kelly SE. Early symptoms and discontinuation among users of oral contraceptives in Sri Lanka. Stud Fam Plann 1984; 15:285-90. [PMID: 6393460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The relationship between symptoms reported during the first two cycles of oral contraceptive use and subsequent discontinuation was studied using data from a comparative clinical trial of two oral contraceptives (standard dose and low dose) in Sri Lanka. Among 24 symptoms considered, the most commonly reported were headache, nausea, irritability, dizziness, tiredness, intermenstrual spotting/bleeding, backache, abdominal pain, vomiting, and hair loss. Headache, nausea, vomiting, and dizziness were closely associated with each other and strongly predictive of discontinuation for both drugs. No other symptoms were consistently associated with each other or with subsequent discontinuation. Intermenstrual spotting/bleeding was associated with later discontinuation of the standard dose preparation, but not the lower dose preparation.
Collapse
|
314
|
Guillebaud J. Are there any absolute medical contraindications to the progestogen only oral contraceptive? BRITISH MEDICAL JOURNAL 1984; 289:1079. [PMID: 6435783 PMCID: PMC1443004 DOI: 10.1136/bmj.289.6451.1079-d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
315
|
Kaiser E. [Effect of a new hormonal contraceptive (Neo-Eunomin) in females with androgenization symptoms]. Geburtshilfe Frauenheilkd 1984; 44:651-5. [PMID: 6083897 DOI: 10.1055/s-2008-1036324] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
The activity of Neo-Eunomin on androgenisation of the skin, seborrhoea, acne, alopecia and hirsutism was investigated in a long-term trial covering 165 patients over 3379 cycles. The age of the patients ranged from 19 to 47 years. The first three symptoms showed clear improvement after 6 months of treatment, and in many cases a cure was achieved after 12 months of therapy. No equally good results could at least be obtained in the treatment of hirsutism. In a further study Neo-Eunomin was compared with a contraceptive containing a nor-testosteron derivative (Conceplan 21). Neo-Eunomin showed convincingly better efficacy in the treatment of androgenisation of the skin than the preparation under comparison.
Collapse
|
316
|
Lachnit-Fixson U. [Progress in oral contraception. Advantages of a levonorgestrel-containing 3-stage preparation over low-dose levonorgestrel and desogestrel containing monophasic combination preparations]. FORTSCHRITTE DER MEDIZIN 1984; 102:825-30. [PMID: 6383993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The three-phase preparation, which contains levonorgestrel, has a number of advantages compared to the traditional monophase combination preparations. With the same contraceptive reliability its cycle stability is very much better than the monophase preparations, which are 40% high dosed in the progestin proportion (levonorgestrel and desogestrel). The dose relations of the new preparation agree with the most recent scientific knowledge on the metabolism aspects of hormonal contraceptives. The hormone dosage in the various phases of the menstrual cycle is largely adapted to the plasma level course of beta-oestradiol and progesterone in the corresponding phases of the normal cycle.
Collapse
|
317
|
Gulati K, Mapa MK, Gupta AN, Singh PM, Devi PK. Norethisterone oenanthate as an injectable contraceptive in two treatment schedules in interval subjects. ASIA-OCEANIA JOURNAL OF OBSTETRICS AND GYNAECOLOGY 1984; 10:281-6. [PMID: 6525083 DOI: 10.1111/j.1447-0756.1984.tb00688.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
318
|
Lisý Z. [Hormonal contraceptives in female rowers]. CASOPIS LEKARU CESKYCH 1984; 123:1086-90. [PMID: 6498900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
319
|
Rivera R, Gaitan JR, Ortega M, Flores C, Hernandez A. The use of biodegradable norethisterone implants as a 6-month contraceptive system. Fertil Steril 1984; 42:228-32. [PMID: 6745456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The effects of a 6-month contraceptive system of biodegradable norethisterone (NET) implants on the menstrual cycle, estradiol and progesterone levels, the presence of side effects, its contraceptive effectiveness, and the NET levels achieved were studied in a group of nine women. There was practically no disruption of the menstrual cycle and no important side effects. Ovulation was inhibited in four subjects, and another four subjects remained ovulatory. In all the subjects a cyclic secretion of estradiol was maintained. No pregnancies occurred. The circulatory levels of NET were very stable throughout the 6-month period of implant use.
Collapse
|
320
|
Seget'a J. [Monogest in gynecologic practice]. CESKOSLOVENSKA GYNEKOLOGIE 1984; 49:496-9. [PMID: 6488351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
321
|
Pasquale SA. Rationale for a triphasic oral contraceptive. THE JOURNAL OF REPRODUCTIVE MEDICINE 1984; 29:560-7. [PMID: 6481710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
322
|
Mintz G, Gutiérrez G, Delezé M, Rodríguez E. Contraception with progestagens in systemic lupus erythematosus. Contraception 1984; 30:29-38. [PMID: 6434228 DOI: 10.1016/0010-7824(84)90076-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
To test the efficacy and tolerance of progestagens as contraceptives in systemic lupus erythematosus (SLE), 200 mg IM norethisterone enanthate was administered to 10 patients, 0.03 mg/day oral levonorgestrel to 15 patients and they were compared with 18 control patients. There were 4 episodes of active SLE in 48 patient-months on norethisterone enantate and 6 episodes in 122 patient-months on levonorgestrel as compared with 9 episodes of active disease in 298 control patient-months (p = ns). There were no pregnancies and intermenstrual bleeding led to discontinuation of medication in 30% of patients. Progestagens may be an alternative contraceptive method in SLE.
Collapse
|
323
|
Earl HM, Rubens RD, Knight RK, Hayward JL. Norethisterone acetate in the treatment of advanced breast cancer. Clin Oncol (R Coll Radiol) 1984; 10:103-9. [PMID: 6734001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
One hundred and twenty-five patients with progressive advanced carcinoma of the breast were treated with norethisterone acetate 20 mg tds orally after prior hormonal treatment or chemotherapy. Ninety-nine patients are evaluable for response. Sixteen patients (16%) achieved a partial response (median duration 4.5 months), 26 (26%) had stable disease (median duration 3 months) and 57 (58%) developed progressive disease on treatment. Patients who responded to norethisterone acetate had more often responded to prior hormonal or ablative treatment (56% vs 25%) and had received less prior treatment than those who did not respond (p less than 0.05). There was no statistically significant correlation between response and age, menopausal status, disease-free interval, stage at diagnosis, or distribution of disease. Side effects led to cessation of therapy in nine patients (9%).
Collapse
|
324
|
Walther Meade C, Perez Michaud Casarin L, Almazan Diaz M, Guzman Aquado A, Samano Zacarias L, Holck S, Diethelm P, Annus J. A clinical study of norethisterone enanthate in rural Mexico. Stud Fam Plann 1984; 15:143-8. [PMID: 6740731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Clinical trials of norethisterone enanthate (NET-EN), a long-acting, injectable progestogen, have demonstrated its short-term safety and effectiveness as a method of contraception in a controlled trial setting. Family planning programs interested in providing NET-EN need information on its efficacy and acceptability under usual field conditions. This first field study of NET-EN was conducted in family planning clinics in rural areas of Mexico. Women admitted to the study were followed up at two-month intervals to receive an injection of 200 milligrams of NET-EN, and to be asked about possible side effects of the drug. Among the 5,792 women recruited, the overall life-table discontinuation rate was 57.0 per 100 women at 12 months and 69.0 at 18 months. The single most common reason for discontinuation was amenorrhea, followed by bleeding problems. Women who were older and who already had several children were most likely to continue using NET-EN. Nine pregnancies were reported during the study, with a cumulative pregnancy rate of 0.3 per 100 women at 18 months. NET-EN appears to be an effective method of contraception that is acceptable to a substantial proportion of women from rural areas in Mexico who choose to use it, when it is provided through a national family planning program.
Collapse
|
325
|
Pulkkinen MO, Düsterberg B, Hasan H, Kivikoski A, Laajoki V. Norethisterone acetate and ethinylestradiol in early human pregnancy. TERATOLOGY 1984; 29:241-9. [PMID: 6429876 DOI: 10.1002/tera.1420290210] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
In a double-blind randomized trial, 25 women (8-9 weeks pregnant) received 20 mg norethisterone acetate (NET-AC) and 0.04 mg ethinylestradiol (EE2), 25 women receiving placebo. The patients were followed by ultrasound and the products at curettage studied macroscopically and microscopically. In an open trial, ten patients (5-9 weeks pregnant) received NET-AC + EE2, 11 serving as controls. The concentrations of plasma progesterone, estradiol-17 beta, 17 alpha-hydroxyprogesterone, norethisterone, and FSH were followed. The frequency of intrauterine hemorrhage in early pregnancy was not affected by NET-AC + EE2. Ultrasound was not reliable when studying the occurrence of decidual hemorrhages during early pregnancy. The pharmacokinetics and bioavailability of NET remain unchanged during early pregnancy. The treatment with NET-AC + EE2 had no effect on the heights and the time courses of the mean plasma values of progesterone, estradiol-17 beta, 17 alpha-hydroxyprogesterone, and FSH. No differences were found between treated and nontreated patients in the pathology of the placenta or decidua as determined by both macroscopic and microscopic examinations. The hypothesis of Papp and Gardo, that decidual hemorrhages may be induced in early pregnancy as a consequence of a "withdrawal effect" of hormonal pregnancy tests, is not supported by the results of this investigation.
Collapse
|